// App-Quantinova.ai

124 : Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Researchers

Presenter

  • Talha Munir

Principal Investigators

  • Nichola Webster

  • Surita Dalal

  • Kristian Brock

  • Francesca Yates

  • Chhaya Sankhalpara

  • Donald Macdonald

  • Christopher Fegan

  • Alison McCaig

  • Anna Schuh

  • Andrew Pettitt

  • John G. Gribben

  • Piers Patten

  • Stephen Devereux

  • Adrian Bloor

  • Christopher P Fox

  • Francesco Forconi

  • Andrew Rawstron

  • Peter Hillmen

Medical Centers

  • St. James's University Hospital, Leeds, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • St. James's University Hospital, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Imperial College, London, United Kingdom

  • University Hospital of Wales, Cardiff, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Royal Liverpool and Broardgreen University Hospital NHS Trust, Liverpool, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

  • King's College Hospital, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • St. James University Hospital, Institute of Oncology, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Hematology-oncology disease

  • Mental retardation, autosomal dominant 4

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved